Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer

Published:2018-10 Issue:10 Volume:21 Page:1259-1268
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

McCool Rachael,Fleetwood Kelly,Glanville Julie,Arber Mick,Goodall Howard,Naidoo Shevani

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference48 articles.

1. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur J Cancer,2013

2. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. [Accessed June 20, 2016].

3. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches;Karantanos;Oncogene,2013

4. Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know;Heidenreich;Eur Urol,2013

5. Sequencing systemic therapies in metastatic castration-resistant prostate cancer;Liu;Cancer Control,2013

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting Treatment Effects from Surrogate Endpoints in Historical Trials in First-Line Metastatic Castration-Resistant Prostate Cancer;Clinical Genitourinary Cancer;2024-10

2. Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer;JAMA Network Open;2024-08-16

3. Abiraterone Acetate Versus Enzalutamide Against Chemo-Naïve Castration-Resistant Prostate Cancer With Full-Dose Induction;Cureus;2024-07-10

4. Abiraterone acetate versus enzalutamide against chemo-naïve castration resistant prostate cancer with full dose induction;2024-04-18

5. Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2024-03-27